Pediatric exclusivity fda 6 months?

Yes. In the U.S. FDA law, “pediatric exclusivity” typically means a six-month extension of a drug’s marketing exclusivity. It is granted if the sponsor conducts pediatric studies in response to an FDA written request and submits the final study results.

Key points:
- Trigger: FDA issues a Written Request (under the Pediatric Exclusivity provision). The sponsor completes the required pediatric studies and submits final reports.
- How long: An extra six months of market protection added to the drug’s existing exclusivity term (not a patent term extension).
- What counts: The pediatric studies must pertain to the approved active ingredient and the related dosage forms/strengths specified in the request. The extension is awarded after FDA reviews the pediatric data.
- Not automatic: If the studies aren’t completed or the data don’t meet requirements, the six-month extension may not be granted.
- Practical effect: Delays generic competition by up to six months for the affected product (and sometimes for related dosage forms, depending on FDA determinations). The status is listed in FDA’s Orange Book.

If you want, I can outline the typical steps for obtaining pediatric exclusivity or explain how to check whether a specific drug has this extension.